A Comparative Study of Target Engagement Assays for HDAC1 Inhibitor Profiling

被引:9
作者
Asawa, Rosita R. [1 ]
Zakharov, Alexey [1 ]
Niehoff, Taylor [1 ]
Chitsaz, Ata [1 ]
Jadhav, Ajit [1 ]
Henderson, Mark J. [1 ]
Simeonov, Anton [1 ]
Martinez, Natalia J. [1 ]
机构
[1] NIH, Natl Ctr Advancing Translat Sci, 9800 Med Ctr Dr, Rockville, MD 20892 USA
基金
美国国家卫生研究院;
关键词
HDAC1; qHTS; profiling; SplitLuc CETSA; NanoBRET; epigenetic compound library; target engagement; HISTONE DEACETYLASES; EXPRESSION; CANCER; FAMILY;
D O I
10.1177/2472555219883625
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Histone deacetylases (HDACs) are epigenetic modulators linked to diseases including cancer and neurodegeneration. Given their therapeutic potential, highly sensitive biochemical and cell-based profiling technologies have been developed to discover small-molecule HDAC inhibitors. Ultimately, the therapeutic action of these inhibitors is dependent on a physical engagement with their intended targets in cellular and tissue environments. Confirming target engagement in the cellular environment is particularly relevant for HDACs since they function as part of cell type-specific multiprotein complexes. Here we implemented two recently developed high-throughput target engagement technologies, NanoBRET and SplitLuc CETSA, to profile 349 compounds in the Epigenetic-Focused collection for HDAC1 binding. We found that the two HDAC1 target engagement assays correlated well with each other and with orthogonal activity-based assays, in particular those carried out in cellular environments rather than with isolated HDAC proteins. The assays detected a majority of the previously described HDAC1 inhibitors in the collection and, importantly, triaged HDAC inhibitors known to target other HDACs.
引用
收藏
页码:253 / 264
页数:12
相关论文
共 34 条
  • [21] Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α
    Kawai, H
    Li, HC
    Avraham, S
    Jiang, SX
    Avraham, HK
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (03) : 353 - 358
  • [22] Kreyszig E., 1979, Advanced engineering mathematics, V10th ed., P880
  • [23] HDACs and HDAC Inhibitors in Cancer Development and Therapy
    Li, Yixuan
    Seto, Edward
    [J]. COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2016, 6 (10):
  • [24] Liao Daiqing, 2015, Drug Discov Today Technol, V18, P24, DOI 10.1016/j.ddtec.2015.10.006
  • [25] Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide:: A new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation
    Mai, A
    Massa, S
    Ragno, R
    Esposito, M
    Sbardella, G
    Nocca, G
    Scatena, R
    Jesacher, F
    Loidl, P
    Brosch, G
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (09) : 1778 - 1784
  • [26] A widely-applicable high-throughput cellular thermal shift assay (CETSA) using split Nano Luciferase
    Martinez, Natalia J.
    Asawa, Rosita R.
    Cyr, Matthew G.
    Zakharov, Alexey
    Urban, Daniel J.
    Roth, Jacob S.
    Wallgren, Eric
    Klumpp-Thomas, Carleen
    Coussens, Nathan P.
    Rai, Ganesha
    Yang, Shyh-Ming
    Hall, Matthew D.
    Marugan, Juan J.
    Simeonov, Anton
    Henderson, Mark J.
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [27] Target engagement and drug residence time can be observed in living cells with BRET
    Robers, Matthew B.
    Dart, Melanie L.
    Woodroofe, Carolyn C.
    Zimprich, Chad A.
    Kirkland, Thomas A.
    Machleidt, Thomas
    Kupcho, Kevin R.
    Levin, Sergiy
    Hartnett, James R.
    Zimmerman, Kristopher
    Niles, Andrew L.
    Ohana, Rachel Friedman
    Daniels, Danette L.
    Slater, Michael
    Wood, Monika G.
    Cong, Mei
    Cheng, Yi-Qiang
    Wood, Keith V.
    [J]. NATURE COMMUNICATIONS, 2015, 6
  • [28] Seethala R, 2009, HDB DRUG SCREENING, pxiii
  • [29] Histone deacetylase 1 expression in gastric cancer
    Sudo, Tomoya
    Mimori, Koshi
    Nishida, Naohiro
    Kogo, Ryunosuke
    Iwaya, Takeshi
    Tanaka, Fumiaki
    Shibata, Kohei
    Fujita, Hiromasa
    Shirouzu, Kazuo
    Mori, Masaki
    [J]. ONCOLOGY REPORTS, 2011, 26 (04) : 777 - 782
  • [30] Sultana F., 2018, CURR MED CHEM, V25